专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016131945A1 COMBINATION PRODUCT WITH AUTOPHAGY MODULATOR 审中-公开
标题翻译：具有自动调节器的组合产品
公开(公告)号：WO2016131945A1
公开(公告)日：2016-08-25
申请号：PCT/EP2016/053522
申请日：2016-02-19
申请人： TRANSGENE SA
发明人： ZAUPA, Cécile , HORTELANO, Julie , SILVESTRE, Nathalie , SPINDLER, Anita
IPC分类号： A61K39/00
CPC分类号： A61K39/00 , A61K2039/555 , A61K2039/55516 , A61K2039/57 , C12N2710/10043 , C12N2710/24143
摘要： The present invention relates to a combination product comprising an autophagy modulator and an antigen, and to the use of the autophagy modulator as an adjuvant for the prophylaxis and the treatment of diseases such as infectious diseases, proliferative diseases and neurodegenerative diseases.
摘要翻译：本发明涉及包含自噬调节剂和抗原的组合产品，以及使用自噬调节剂作为预防和治疗疾病如感染性疾病，增殖性疾病和神经变性疾病的佐剂。

2. 发明申请

WO2018234506A2 PERSONALIZED VACCINE 审中-公开
公开(公告)号：WO2018234506A2
公开(公告)日：2018-12-27
申请号：PCT/EP2018/066668
申请日：2018-06-21
申请人： TRANSGENE SA
发明人： BENDJAMA, Kaïdre , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste , GRELLIER, Benoît
IPC分类号： A61K39/00 , A61P35/00 , C12N7/00
摘要： The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy, specifically for stimulating T cell immune response.

3. 发明申请

WO2020049001A1 NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF 审中-公开
公开(公告)号：WO2020049001A1
公开(公告)日：2020-03-12
申请号：PCT/EP2019/073488
申请日：2019-09-03
申请人： BIOINVENT INTERNATIONAL AB , TRANSGENE SA
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , SEMMRICH, Monika , MÅRTENSSON, Linda , HOLMKVIST, Petra , MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie
IPC分类号： C07K16/28 , A61P37/02 , A61P35/00
摘要： Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

4. 发明申请

WO2015104380A1 FUSION OF HETEROOLIGOMERIC MYCOBACTERIAL ANTIGENS 审中-公开
标题翻译：异氟烷抗体的融合
公开(公告)号：WO2015104380A1
公开(公告)日：2015-07-16
申请号：PCT/EP2015/050344
申请日：2015-01-09
申请人： TRANSGENE SA
发明人： MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie , PENIN, François
IPC分类号： A61K39/04 , C07K16/12
CPC分类号： A61K39/04 , A61K45/06 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C07K14/35 , C07K16/1289 , C07K2317/34 , C07K2319/00 , C07K2319/035 , C12N2710/24141
摘要： The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.
摘要翻译：本发明一般涉及包含或编码至少两种异寡分子分枝杆菌抗原的新型免疫原性组合，优选包含所述两种异源寡分支分枝杆菌抗原的融合多肽，其中分枝杆菌抗原选自分枝杆菌属物种的Esx，PE和PPE抗原，特别是结核分枝杆菌复合物如结核分枝杆菌（Mtb）的分枝杆菌。本发明还涉及包含或编码所述免疫原性组合的载体，宿主细胞和组合物以及用于表达和产生它的方法。本发明还涉及使用所述免疫原性组合，融合多肽，载体，宿主细胞，组合物特别用于诱导或刺激免疫应答的方法，其目的是提供针对分枝杆菌感染的保护性应答或由分枝杆菌感染。

5. 发明申请

WO2016008976A1 ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS 审中-公开
标题翻译：用于表达免疫检查点调节剂的ONCOLYTIC病毒
公开(公告)号：WO2016008976A1
公开(公告)日：2016-01-21
申请号：PCT/EP2015/066263
申请日：2015-07-16
申请人： TRANSGENE SA
发明人： SILVESTRE, Nathalie , GEIST, Michel , RITTNER, Karola , MARCHAND, Jean-Baptiste , THIOUDELLET, Christine
IPC分类号： A61K35/768 , C07K16/18
CPC分类号： A61K35/768 , A61K9/0019 , A61K35/761 , A61K35/763 , A61K35/765 , A61K35/766 , A61K45/06 , A61K2039/505 , C07K14/535 , C07K16/18 , C07K16/2818 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/622 , C12N7/00 , C12N9/1077 , C12N9/80 , C12N2710/24121 , C12N2710/24132 , C12Y204/02009 , C12Y305/01023
摘要： The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
摘要翻译：本发明提供了包含编码一种或多种免疫检验点调节剂的核苷酸序列的溶瘤病毒。它还涉及包含有效量的所述溶瘤病毒和最终药学上可接受的载体及其用于治疗增殖性疾病如癌症的用途的药物组合物。

6. 发明申请

WO2013007772A1 HBV POLYMERASE MUTANTS 审中-公开
标题翻译： HBV聚合酶突变体
公开(公告)号：WO2013007772A1
公开(公告)日：2013-01-17
申请号：PCT/EP2012/063640
申请日：2012-07-12
申请人： TRANSGENE SA , MARTIN, Perrine , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste
发明人： MARTIN, Perrine , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste
IPC分类号： C12N9/22 , A61K38/16 , C07K14/02 , C12N5/10 , A61K39/29 , A61P31/12
CPC分类号： C12N9/1252 , A61K38/00 , A61K39/292 , A61K2039/53 , C07K14/005 , C07K2319/02 , C07K2319/03 , C07K2319/40 , C12N7/00 , C12N9/1276 , C12N9/22 , C12N2730/10122 , C12N2730/10134 , C12N2799/022 , C12N2799/023 , C12P21/02 , C12Y207/07007 , C12Y301/26004
摘要： The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.
摘要翻译：本发明涉及聚合酶HBV突变体多肽，其包含功能性地破坏聚合酶活性的突变聚合酶结构域和包含该聚合酶突变体多肽的融合蛋白。本发明还涉及用于表达所述聚合酶突变体多肽的核酸分子和表达载体以及可用于引发对HBV的免疫应答的组合物，目的是提供对HBV感染的保护或治疗作用。

7. 发明申请

WO2011015656A2 COMPOSITION FOR TREATING HBV INFECTION 审中-公开
标题翻译：用于治疗HBV感染的组合物
公开(公告)号：WO2011015656A2
公开(公告)日：2011-02-10
申请号：PCT/EP2010/061492
申请日：2010-08-06
申请人： TRANSGENE SA , MARTIN, Perrine , INCHAUSPE, Geneviève , SILVESTRE, Nathalie , SCHMITT, Doris
发明人： MARTIN, Perrine , INCHAUSPE, Geneviève , SILVESTRE, Nathalie , SCHMITT, Doris
IPC分类号： A61K39/29 , A61P31/12
CPC分类号： A61K39/29 , A61K39/12 , A61K39/292 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N7/00 , C12N9/1252 , C12N15/86 , C12N2710/10043 , C12N2710/24143 , C12N2730/10134 , C12Y207/07007
摘要： The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.
摘要翻译：本发明提供包含乙型肝炎病毒（HBV）组分的组合物，其可以是基于核酸或多肽的核酸分子以及编码这样的HBV组分的载体。它还涉及包含这种核酸分子或载体的感染性病毒颗粒和宿主细胞。它还提供包含这种核酸分子，载体，感染性病毒颗粒或宿主细胞的组分和试剂盒以及用于预防或治疗HBV感染的治疗用途。

8. 发明申请

WO2018234506A3 PERSONALIZED VACCINE 审中-公开
公开(公告)号：WO2018234506A3
公开(公告)日：2018-12-27
申请号：PCT/EP2018/066668
申请日：2018-06-21
申请人： TRANSGENE SA
发明人： BENDJAMA, Kaïdre , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste , GRELLIER, Benoît
IPC分类号： A61K39/00 , A61P35/00 , C12N7/00
摘要： The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy, specifically for stimulating T cell immune response.

9. 发明申请

WO2014009438A2 MYCOBACTERIAL ANTIGEN VACCINE 审中-公开
公开(公告)号：WO2014009438A2
公开(公告)日：2014-01-16
申请号：PCT/EP2013/064624
申请日：2013-07-10
申请人： TRANSGENE SA
发明人： TUPIN, Emmanuel , MICOL, Romain , COUPET, Charles Antoine , INCHAUPSE, Geneviève , GOUANVIC, Marie , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste , BENY, Cécile
IPC分类号： A61K39/04
CPC分类号： A61K39/04 , A61K2039/51 , A61K2039/53 , C07K14/35 , C07K16/1289 , C07K2319/00 , C07K2319/40
摘要： The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection. The present invention also concerns antibodies directed to such mycobacterial antigens and fusion polypeptides that can be used in the diagnosis of a Mycobacterium infection and method of detection as well as kits of reagent comprising said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions or antibodies.
摘要翻译：本发明一般涉及包含至少五种分枝杆菌属物种的抗原及其融合物的免疫原性组合，以及编码这种组合抗原和融合物的核酸分子。本发明还涉及包含或编码所述分枝杆菌抗原和融合多肽组合的核酸分子，载体，宿主细胞和组合物，以及用于重组产生它们的方法。本发明还涉及使用所述分枝杆菌抗原，融合多肽，载体，宿主细胞，组合物特别用于诱导或刺激针对分枝杆菌感染或由分枝杆菌感染引起或与其相关的任何疾病的免疫应答的组合的方法。本发明还涉及可用于诊断分枝杆菌感染的此类分枝杆菌抗原和融合多肽的抗体和检测方法以及包含所述分枝杆菌抗原组合，融合多肽，载体，宿主细胞，组合物或抗体。

10. 发明公开

EP2588596A2 IMMORTALIZED AVIAN CELL LINES 审中-公开
标题翻译：意大利VOGELZELLLINIEN
公开(公告)号：EP2588596A2
公开(公告)日：2013-05-08
申请号：EP11738998.1
申请日：2011-06-29
申请人： Transgene SA
发明人： ERBS, Philippe , KAPFER, Marina , SILVESTRE, Nathalie
IPC分类号： C12N7/02 , C12N15/90 , C12N5/16
CPC分类号： C12N5/0018 , C12N5/0602 , C12N7/00 , C12N15/907 , C12N2510/02 , C12N2510/04 , C12N2710/24052 , C12N2710/24152 , C12N2760/16152 , C12N2760/16252 , C12N2800/80
摘要： This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式